New Compound Shrinks Fat, Drops Inflammation and Blocks Sugar (50mg daily)

Taxifolin (also known as dihydroquercetin) is a flavonoid found in certain plants like Siberian larch and milk thistle. Animal studies over the past decade hinted at thermogenic and anti-inflammatory properties, but the 2025 Nutrients trial changed the landscape by providing the first statistically significant human data. In that study, 62 participants who took 300 mg/day lost an average of 1.6 kg versus 0.3 kg in controls, with HDL cholesterol rising and no adverse effects. These results are remarkable because they occurred without dietary restrictions or exercise mandates—participants simply added the supplement. The metabolic improvements suggest taxifolin doesn’t just aid weight loss; it helps correct the underlying metabolic dysregulation. DeLauer, who struggled with metabolic health in the past, frames this as a tool to support—not replace—the hard work of lifestyle change. He suggests it may be used cyclically to help the body ‘get back on track’ when metabolic function falters.

DeLauer positions cold exposure as a natural way to reinforce taxifolin’s BAT activation. He notes that if you’re already doing cold showers or ice baths, adding taxifolin creates a synergistic environment where the metabolic pathway is already ‘turned on’ by the cold, and the supplement further amplifies the gene expression. This approach aligns with the concept of hormetic stress: a mild stressor (cold) plus a dietary activator yields greater adaptive benefits. He does not provide a specific protocol for cold exposure but emphasizes that it’s one of several lifestyle levers that enhance the compound’s effects.

DeLauer mentions that because taxifolin and berberine ‘converge on the same metabolic switch,’ taking them together produces a synergistic effect. This is particularly useful for those who still struggle with blood sugar regulation despite using berberine alone. He emphasizes that taxifolin doesn’t just add another AMPK activator; it also cleans up the oxidative and inflammatory ‘noise’ that can blunt the body’s response to berberine. While he doesn’t give a precise stack, the logic is that berberine handles glucose, while taxifolin defends the infrastructure.

DeLauer frames this synergy as defense-in-depth: omega-3s quell inflammatory initiation, while taxifolin strengthens the body’s own antioxidant systems and blocks downstream inflammatory mediators. This is particularly relevant because chronic inflammation is a major saboteur of weight loss, impairing AMPK, insulin signaling, and mitochondrial function. By layering taxifolin and omega-3s, you address both the fire and the fire starters. He suggests that the combination goes beyond simple addition, making each more effective because the anti-inflammatory environment is less hostile.

Throughout the video, DeLauer repeatedly emphasizes that taxifolin is ‘awesome, but it’s not a magic bullet.’ He insists that fasting, exercise, sauna, sleep, stress management, and food quality ‘always come first.’ This protocol is less about a specific action and more about reinforcing that any targeted metabolic intervention must be built on a solid base. He mentions that disrupted sleep, for example, is ‘one of the biggest sabotagers of your metabolic health,’ linking to a separate resource on waking up at night. The underlying message: fix the fundamentals, then amplify with tools like taxifolin.

The study followed 62 participants over 6 months. Half voluntarily supplemented with 300 mg of taxifolin daily, while the other half did not. The supplement group lost an average of 1.6 kg, compared to just 0.3 kg in controls. Critically, their HDL cholesterol increased while the control group’s HDL dropped, pointing toward genuine metabolic improvement rather than simple water or glycogen loss. Equally important, there were no reported adverse events—no elevated liver enzymes, no gastrointestinal distress—indicating a strong safety profile. This study shifts taxifolin from an interesting nutraceutical to a clinically supported tool for metabolic health, especially for those stuck in weight-loss plateaus or experiencing metabolic sluggishness.

The 2023 Nutrients paper first identified that taxifolin flips on a trio of genes critical for BAT thermogenesis: uncoupling protein 1 (UCP1) dissipates mitochondrial proton gradients as heat instead of ATP, PGC1α drives mitochondrial biogenesis, and PRDM16 orchestrates the browning of white adipocytes. By increasing mitochondrial density and uncoupling, the drug effectively turns up the body’s combustion at rest—‘upgrading from a Prius to a Lamborghini,’ as DeLauer puts it. This explains how a modest daily dose can lead to a cumulative energy deficit without forcing dietary restriction or stimulant-driven heart rate increases. The process also helps explain why HDL rose in the human trial, as BAT activation is linked to healthier lipid profiles.

By increasing FGF-21, taxifolin essentially tells the body it is in an energy deficit, activating AMPK and shifting metabolism toward fat burning. This hormonal signal coordinates with BAT activation: FGF-21 released from the liver acts on brown fat to further upregulate thermogenic genes. The result is a systemic shift—higher energy expenditure, better glucose control, and reduced fat storage. DeLauer compares it to activating the same pathways that fasting or cold exposure trigger, but without the stress of those interventions. The dual action of direct BAT gene activation and FGF-21 amplification creates a robust, self-reinforcing metabolic loop.

The mechanism entails taxifolin activating the PI3K/AKT signaling cascade, which is the same route insulin normally uses, while simultaneously stimulating AMPK—a energy-sensing enzyme that also promotes GLUT4 translocation. These dual activations result in glucose transporters moving to the cell surface, pulling glucose into muscle cells without a proportionate insulin spike. This reduces the overall insulin burden on the pancreas, lowers postprandial blood sugar excursions, and shifts the body away from storing excess carbohydrates as fat. Together with increased fat oxidation from BAT activation, this creates a metabolic environment where energy substrates are burned rather than stored, directly addressing the ‘idle’ metabolism DeLauer describes.

A study in International Immunopharmacology demonstrated that taxifolin activates the NRF2 pathway, which triggers the production of endogenous antioxidants like glutathione and superoxide dismutase, and dampens pro-inflammatory transcription factors such as NF-κB and MAPK. Another paper in the Chinese Herbal Medicine journal reported reductions in TNF-α, COX-2 (the target of ibuprofen), and VEGF. By simultaneously upregulating the body’s built-in antioxidant network and dialing down multiple inflammatory cascades, taxifolin removes the molecular ‘brakes’ on metabolic function. This explains why the human trial saw sustained benefits over months: the compound creates a favorable milieu where thermogenesis, insulin sensitivity, and fat oxidation can occur without constant inflammatory disruption.